Loading...
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
ABSTRACT: The terminal complement protein (C5) inhibitor eculizumab (Soliris(®)) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) ser...
Na minha lista:
| Udgivet i: | Drugs |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer International Publishing
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7183484/ https://ncbi.nlm.nih.gov/pubmed/32266705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01297-w |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|